Ashley Gallagher, Associate Editor

Investigators find that despite the same quantity of respiratory syncytial virus and presentation, some of the samples demonstrated signs of greater damage to cells.

Analysis of central Missouri discovers differences in co-infection occurrence between Delta and Omicron variants.

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4.

Under specific circumstances and criteria, they are adjustable to approximate OS in selected populations of Canadian patients who have advanced non–small cell lung cancer.

Analysis indicates that a 25-mg dose reduces the condition scores significantly more than a 1mg dose over a 3-week period, but the 10-mg dose did not yield the same results.

Improvement is seen with a higher suspicion of disease and extended timelines, analysis demonstrates.

These show promise as markers to help identify individuals with the conditions and develop targeted therapeutic options.

Analysis includes an overview of the epidemiology, expression, and treatment of human papillomavirus infections during both gestation and childhood.

Four individuals in a new study achieve improvement, with a 35% to 70% reduction in PASI scores.

Agency expects the highest level of activity in the south-central and Southeast areas of the United States.

Phase 3 trial evaluated luspatercept-aamt and shows highly statistically significant and clinically meaningful improvement in red blood cell transfusion for those with myelodysplastic syndromes.

ART also results in a faster decay of plasma HIV RNA and increased HIV CD8+T cell immunity compared with the treatment alone, investigators found.

New clinical outcomes from BICSTaR study indicate sustained impact of the therapy for individuals with HIV.

Results demonstrate improved progression-free survival in the overall patient population and in a prespecified biomarker subgroup of tumors with alterations in specific genes, AstraZeneca says.

Findings are encouraging for individuals with cancer who are receiving immune checkpoint inhibition treatment and want to get a third vaccine dose, investigators said.

Phase 2 APPLY-PNH trial shows positive results superiority vs anti-C5 treatment in adult patients with PNH with residual anemia despite prior therapy.

Study results indicate durable immune response from bivalent booster after 3 months of follow-up.

Highest prevalence is seen among adults, outpatients, and women and can cause persistent severe anosmia or hyposmia, findings indicate.

News research results in Zambia also find that early intervention in the form of antiretroviral therapies and better nutrition may help close the gap.

However, lack of access and awareness about pre-exposure prophylaxis, medication cost, and underestimating disease risk are all barriers to PrEP.

CMD drugs understands that pharmacists are on the front lines with patients, necessitating strong communication with providers.

Investigators examined the impact of daily oral tenofovir disoproxil fumarate in combination with emtricitabine to see the effect on the microbiota in South African women.

By targeting the viral conical core, these ARTs could disrupt the process of assembly and/or disassembly of the virus and result in its suppression.

Case studies highlight recent developments and trends in pharmacologic treatments for migraine.

At month 6 post-COVID-19 infection, 123 patients received a diagnosis of type 1 diabetes (T1D) and only 72 were diagnosed with T1D at 6 months post-non-COVID-19 respiratory infection.

New treatments for chronic migraine have been increasing, with robust evidence for eptinezumab, erenumab, fremanezumab, galcanezumab, and onabotulinumtoxin A.

Investigators found that lifestyle changes such as a high-quality diet and regular exercise can lower the risk of type 2 diabetes in women with a history of gestational diabetes mellitus.

The drug shows improvement in exercise capacity and key secondary outcomes compared with the placebo when added to background therapy for those with pulmonary arterial hypertension.

Investigators found that 25% of patients with heart failure with reduced ejection fraction received guideline-recommended intravenous fluids compared to 37% who did not have the condition.

Investigators find that individuals with both conditions are more likely to develop severe disease than those in the control group.